Literature DB >> 31225756

The Human Right to Science and the Regulation of Human Germline Engineering.

Andrea Boggio1, Bartha M Knoppers2, Jessica Almqvist3, Cesare P R Romano4.   

Abstract

There is currently no international consensus on how human germline engineering should be regulated. Existing national legislation fails to provide the governance framework necessary to regulate germline engineering in the CRISPR era. This is an obstacle to scientific and clinical advancements and inconsistent with human rights requirements. To move forward, we suggest that the human right to science is an ideal starting point for building consensus, at the national and international levels, on governing principles that promote responsible scientific and technological advancements. Regulatory frameworks must recognize the international nature of modern germline genome engineering research, the need for shared governance rather than tech-locked prohibitions, and the fact that humans are not their germline.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31225756     DOI: 10.1089/crispr.2018.0053

Source DB:  PubMed          Journal:  CRISPR J        ISSN: 2573-1599


  4 in total

1.  Societal and Ethical Impacts of Germline Genome Editing: How Can We Secure Human Rights?

Authors:  Jodi Halpern; Sharon E O'Hara; Kevin W Doxzen; Lea B Witkowsky; Aleksa L Owen
Journal:  CRISPR J       Date:  2019-10

Review 2.  Human germline genome editing is illegal in Canada, but could it be desirable for some members of the rare disease community?

Authors:  Erika Kleiderman; Ian Norris Kellner Stedman
Journal:  J Community Genet       Date:  2019-08-16

3.  The 'serious' factor in germline modification.

Authors:  Erika Kleiderman; Vardit Ravitsky; Bartha Maria Knoppers
Journal:  J Med Ethics       Date:  2019-07-20       Impact factor: 2.903

4.  Germline genome editing: Moratorium, hard law, or an informed adaptive consensus?

Authors:  Terry Kaan; Vicki Xafis; G Owen Schaefer; Yujia Zhu; Markus K Labude; Ruth Chadwick
Journal:  PLoS Genet       Date:  2021-09-09       Impact factor: 5.917

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.